Chen, Da-Yuan http://orcid.org/0000-0002-1957-3330
Chin, Chue Vin
Kenney, Devin
Tavares, Alexander H.
Khan, Nazimuddin
Conway, Hasahn L. http://orcid.org/0000-0001-7328-3521
Liu, GuanQun http://orcid.org/0000-0003-2520-7625
Choudhary, Manish C.
Gertje, Hans P.
O’Connell, Aoife K. http://orcid.org/0000-0001-7027-4267
Adams, Scott http://orcid.org/0000-0002-1472-0223
Kotton, Darrell N. http://orcid.org/0000-0002-9604-8476
Herrmann, Alexandra
Ensser, Armin
Connor, John H. http://orcid.org/0000-0002-8867-7256
Bosmann, Markus http://orcid.org/0000-0003-2773-1033
Li, Jonathan Z. http://orcid.org/0000-0001-9914-9662
Gack, Michaela U. http://orcid.org/0000-0002-2163-2598
Baker, Susan C. http://orcid.org/0000-0001-6485-8143
Kirchdoerfer, Robert N. http://orcid.org/0000-0002-5974-2709
Kataria, Yachana
Crossland, Nicholas A. http://orcid.org/0000-0003-3873-9188
Douam, Florian
Saeed, Mohsan http://orcid.org/0000-0001-8505-7054
Article History
Received: 16 March 2022
Accepted: 4 January 2023
First Online: 11 January 2023
Competing interests
: R.N.K. is an inventor on US patent 10,960,070B2, entitled ‘Prefusion coronavirus spike proteins and their use’. M.S. is an inventor on a pending patent entitled ‘Immunogenic compositions and use thereof’ (USSN: 17/463,429). Y.K. received unrelated funding from Abbott Laboratories to assess the durability of SARS-CoV-2 antibodies for healthcare workers. M.B. received funds from ARCA Biopharma for unrelated COVID-19 research. F.D. received funding from Moderna, Flagship Pioneering and ARCA Biopharma for unrelated research. The remaining authors declare no competing interests.
Free to read: This content has been made available to all.